Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

The management of anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) exemplifies the potential of a precision medicine approach to cancer care. The ALK inhibitor crizotinib has led to improved outcomes in the first- and second-line setting; however, toxicities, intracran...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Phu N., Klempner, Samuel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127851/
https://www.ncbi.nlm.nih.gov/pubmed/27965961
http://dx.doi.org/10.3389/fmed.2016.00065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127851/
https://www.ncbi.nlm.nih.gov/pubmed/27965961
http://dx.doi.org/10.3389/fmed.2016.00065

Ejemplares similares